Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology
-$0.05 today
- Market cap
- $144.07M
- Beta
- 1.45
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.48
Volume 1.15M
Average 0.73M
TARA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Protara Therapeutics, Inc.NASDAQ: TARA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $90K rose 8.4% year over year, behind the +11.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +8.4% toward the trailing-twelve-month pace of +11.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 362K USD
- Year-over-year change
- +9.0%
- 4-year CAGR
- +32.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 362K | +9.0% |
| FY2024 | 2024-12-31 | 332K | -2.6% |
| FY2023 | 2023-12-31 | 341K | +37.5% |
| FY2022 | 2022-12-31 | 248K | +112.0% |
| FY2021 | 2021-12-31 | 117K | — |
Depreciation & Amortization vs competitors
How TARA compares with its peers on the latest reported figures
- TARA's LTM Mar 2026 depreciation & amortization of $369K is the 7th largest of the 10 companies compared; the peer median is $1.88M.
- Its year-over-year change of +11.1% is the 4th highest of 9, against a peer median of +3.3%.
- Over three fiscal years its annual growth of +13.4% compares with a peer median of +6.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.65M | +1.1% | +6.0% | 81.8% | |
| LTM Mar 2026 | $6.75M | +171.1% | -20.0% | 8.6% | |
| LTM Mar 2026 | $6.56M | -25.2% | -28.2% | 19.0% | |
| LTM Mar 2026 | $1.88M | -43.4% | +65.8% | 3.4% | |
| LTM Mar 2026 | $1.88M | +27.6% | +10.4% | 13.0% | |
| LTM Mar 2026 | $1.53M | +180.4% | +0.4% | 9.2% | |
| LTM Mar 2026 | $369K | +11.1% | +13.4% | — | |
| LTM Mar 2026 | $334K | +5.4% | +13.8% | 1.0% | |
| LTM Sep 2026 | $152K | -97.9% | — | — | |
| LTM Mar 2026 | $142.16K | — | — | — | |
| Peer median (excluding TARA) | $1.88M | +3.3% | +6.0% | 9.2% | |
Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Depreciation & Amortization | 117K | 248K | 341K | 332K | 362K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.36M | 6.69M | 6.09M | 4.13M | 3.83M |
| Change in Working Capital | 534K | 539K | (4.14M) | 4.01M | (2.94M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 40K | 631K | 848K | 1.38M | (873K) |
| Other Working Capital | 494K | (92K) | (4.99M) | 2.63M | (2.07M) |
| Other Non-Cash Items | 1.74M | 32.02M | 569K | 324K | (173K) |
| Operating Cash Flow | (34.5M) | (26.46M) | (37.56M) | (35.81M) | (56.37M) |
| Capital Expenditures | (596K) | (120K) | (45K) | (63K) | (94K) |
| Acquisitions (Net) | 97.6K | (15.07K) | 0 | 0 | 0 |
| Purchases of Investments | (124.75M) | (43.55M) | (12.19M) | (29.38M) | (204.63M) |
| Sales of Investments | 27.15M | 58.62M | 65.34M | 48.6M | 65.23M |
| Other Investing Activities | (97.6K) | 15.07K | 0 | 0 | 0 |
| Investing Cash Flow | (98.19M) | 14.95M | 53.11M | 19.16M | (139.49M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 136.01M | 82.9M |
| Common Stock Repurchased | (228K) | (90K) | (91K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 3.86M | (185K) |
| Financing Cash Flow | (228K) | (90K) | (91K) | 139.87M | 82.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (132.92M) | (11.6M) | 15.46M | 123.21M | (113.14M) |
| Free Cash Flow | (35.1M) | (26.58M) | (37.6M) | (35.87M) | (56.46M) |
Protara Therapeutics, Inc.
NASDAQ:TARA
Intrinsic Alpha fair value
Locked
Current Price
$2.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.